COVID-19 Vaccination

Last updated 12th October 2021

Myhealth Hampton and Myhealth Mentone are approved COVID-19 vaccination centres.

We are a Pfizer AND AstraZeneca vaccination centre

Myhealth Hampton and Myhealth Mentone are approved COVID-19 vaccination centres.

Myhealth Hampton and Myhealth Mentone are now accepting bookings for COVID-19 vaccination. If you cannot book at a suitable time, please check back after a few days as we will continually open further vaccination sessions according to demand and staffing.

This web page is solely for accessing the COVID-19 vaccine at Myhealth Hampton or Myhealth Mentone.

For all other matters, please visit our main web pages at Hampton or Mentone

3rd dose of COVID Vaccine for people with SEVERE immune deficiency

UPDATE 12th October 2021

The Australian Technical Advisory Group on Immunisation (ATAGI) have made a recommendation on 7 October 2021 that all people aged 12 and over with a severe immune deficiency have a third COVID-19 vaccination dose to complete their primary immunisation.

This is to address the risk of suboptimal or non-response to the two dose schedule in this group.  

This third primary dose is NOT to be considered a booster dose for the general population. It is a third dose – to complete the regular course of vaccination – for a very specific cohort of vulnerable people to ensure they have the highest level of protection available against COVID-19.

The third dose should occur 2 – 6 months after the second dose.

An mRNA vaccine (Pfizer or Moderna) is recommended for the third dose but AstraZeneca may be used if the first two doses were AstraZeneca

ATAGI have provided specific guidelines to medical practitioners regarding suitability criteria for a third dose.

This includes people with

  • Blood cancer or Cancer patients on active treatment with Chemotherapy or Radiotherapy  
  • Immune Suppressant Treatments (While receiving the first two vaccine doses) eg For some Rheumatological conditions and high dose steroids.  This includes but is not limited to the following treatments; Mycophenalate, Methotrexate, Leflunomide, Azathioprine, 6 Mercaptopurine, Cyclophosphamide, Chlorambucil, Cyclopsporin, Tacrolimus, Fingolimod, Alemtuzamab, Eculizumab, Abatacept, High dose Prednisolone (more than 20mg daily) or Dexamethasone. 
  • Stem cell transplant patients
  • Organ Transplant patients taking immune suppressants
  • Patients on Dialysis
  • Other patients eg HIV and other Primary immune deficiency disorders

The practice has dedicated vaccine clinic time for patients in this category.

Detailed information on the criteria from ATAGI may be found at this link : https://www.health.gov.au/news/atagi-statement-on-the-use-of-a-3rd-primary-dose-of-covid-19-vaccine-in-individuals-who-are-severely-immunocompromised

Please note: If a person’s immunosuppressive therapy was commenced more than two weeks AFTER their second vaccine dose then a third dose is not required because the immune response to the vaccine is considered adequate.

If you believe that you are eligible for this third dose then please book a Telehealth consult with your GP either via our website or via the MyPractice Phone App which may be downloaded via the link below.    This consultation will be bulk-billed if it is solely to discuss your vaccine eligibility for the third dose.  

We strongly recommend that your specific medical requirements are properly discussed before proceeding with this third dose of vaccine.  During your teleheath appointment, your doctor will book your vaccine appointment time once satisfied that the necessary criteria are met and that it is safe for you to proceed to have the third dose.

MyPractice Phone App

Before you may receive your vaccine, there are a number of steps to be undertaken.

STEP 1 – Preliminary Tasks

You must have a valid Medicare number in order for you to receive the vaccine at our practice. If you are an overseas visitor and do not have a Medicare number, you are still eligible to receive the vaccine but via other avenues.

Information for DVA Care holders
  • If you have a Veteran Gold Card, bring that. 
  • If you have a Veteran White Card, bring your Medicare card as well. 
  • If you have a Veteran Orange Card, just bring your Medicare card. 
  • If you don’t have a Medicare card and you don’t know your Medicare number, phone Medicare on 132 011. 
  • If you don’t have a Medicare number, you can still get the COVID-19 vaccine. We recommend you call Medicare on 132 011 first, to check you are not enrolled with Medicare already. The staff member will help you to either enrol in Medicare or to apply for an Individual Healthcare Identifier (IHI) if you don’t already have one.
  • Even if you are not in Medicare, you will have an IHI if you get a DVA pension or benefit.

People who are not eligible for Medicare, for example a temporary resident, will need to attend a state- or territory-run vaccination clinic to get their COVID-19 vaccines. 

You can find more information about getting an IHI at https://servicesaustralia.gov.au/ihs on the Services Australia website. 

More information about this is below:

Services Australia – Get Ready for Your COVID-19 Vaccinations
https://www.servicesaustralia.gov.au/individuals/news/get-ready-your-covid-19-vaccinations

What Should I Do Before I Get Vaccinated for COVID-19 ?
https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/learn-about-covid-19-vaccines/what-should-i-do-before-i-get-vaccinated-for-covid-19

STEP 2 – Check Your Eligibility for the Vaccine

We will be administering the COVID-19 vaccine to anyone who is deemed eligible under the government directives. Eligibility will change over time according to vaccine supply and other factors.

Click to use the Vaccine Eligibility Checker

https://covid-vaccine.healthdirect.gov.au/eligibility

Updated information on who is eligible to receive the vaccine may be found at this link

https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/getting-vaccinated-for-covid-19/when-will-i-get-a-covid-19-vaccine

Patients who are eligible may also access the COVID-19 vaccines via one of the state-run vaccination hubs.  

State-run vaccination centres are listed at this web address:
https://www.coronavirus.vic.gov.au/vaccination-centres

Learn more about the vaccination phases and eligibility

STEP 3 – Vaccine Information and Consent

This step asks you to read about potential side effects of the vaccine and to discuss with your usual doctor about any safety or side-effect concerns that you may have.

People who have a COVID-19 vaccination have a much lower chance of getting sick from the disease called COVID-19.

The COVID-19 vaccination is free. You choose to have the vaccination or not.

To be vaccinated you will get a needle in your arm. You need to have the vaccination two times on different days. There are different brands of vaccine. You need to have the same brand of vaccine both times.

The COVID vaccine must be given as a separate dose from any other vaccine by at least 7 (seven) days.

COVID-19 Vaccine consent form
It is not crucial for this form to be signed but is recommended if the person receiving the vaccine cannot provide verbal consent on their own behalf ( eg dementia or intellectual disability patients)

Information on this form is relevant to your understanding of the vaccine.
https://www.health.gov.au/resources/publications/covid-19-vaccination-consent-form-for-covid-19-vaccination

Vaccination is voluntary and free. You can discuss any concerns or questions you have about COVID-19 vaccination with your immunisation provider and/or your GP before you receive the vaccine.

YOU CANNOT MIX VACCINE DOSES. YOU MUST HAVE THE SAME BRAND OF VACCINE FOR DOSE 1 AND DOSE 2. THE ONLY EXCEPTION TO THIS IS IF YOU HAVE HAD A MEDICALLY SERIOUS REACTION TO THE FIRST VACCINE DOSE.

About the AstraZeneca Vaccine (Vaxzevria)

Vaxzevria Vaccine by AstraZeneca can prevent people from becoming ill from COVID-19. This vaccine does not contain any live SARS-CoV-2 virus, and cannot give you COVID-19. It contains the genetic code for an important part of the SARS-CoV-2 virus called the spike protein. This code is inserted into a harmless common cold virus (an adenovirus), which brings it into your cells. Your body then makes copies of the spike protein, and your immune system learns to recognise and fight the SARS-CoV-2 virus. The adenovirus has been modified so that it cannot replicate once it is inside cells. This means it cannot spread to other cells and cause infection. 

ATAGI advice on COVID-19 AstraZeneca vaccine

The Australian Technical Advisory Group on Immunisation (ATAGI) recommends the COVID-19 vaccine by Pfizer (Comirnaty) is preferred in adults aged under 60 years.
In people 60 years and over, ATAGI continue to advise that the benefits of vaccination with the AstraZeneca vaccine outweigh the risks associated with vaccination.

This recommendation is based on:

  • the increasing risk of severe outcomes from COVID-19 in older adults (and hence a higher benefit from vaccination), and
  • the increased risk of thrombosis with thrombocytopenia following AstraZeneca vaccine in those under 60 years.

There appears to be a small risk of TTS in people 60 years and over, but this risk appears to be lower than in younger people. Cases overseas have been reported at all ages.

If you have already had your first dose of the AstraZeneca vaccine, and did not experience abnormal side effects, ATAGI recommends you still receive your second AstraZeneca dose. This will provide you with greater coverage against severe illness from COVID-19.

People who are considering vaccination with AstraZeneca COVID-19 vaccine should be aware of this potential complication as part of providing informed consent.

The COVID-19 AstraZeneca vaccine can be used in adults aged under 60 years where the benefits clearly outweigh the risk for that individual and the person has made an informed decision based on an understanding of the risks and benefits. We recommend that you discuss this with your doctorate decide whether this vaccine is indicated for yourself if you are aged under 60 years.

Read statements about the updated advice from ATAGI on 17 June from:

As part of Australia’s COVID-19 Vaccine and Treatment Strategy, the Australian Government has secured 53.8 million doses of the AstraZeneca vaccine, with 50 million to be manufactured onshore.

Read about the TGA’s provisional approval of the AstraZeneca vaccine.

Receiving the AstraZeneca vaccine

Any person aged 18 or over may receive the AstraZeneca Vaccine

Two doses of the Astra/Zeneca vaccine are required between 4 and 12 weeks apart.

Drawing on the advice of the TGA and also from the implementation of the program internationally, our Australian Technical Advisory Group on Immunisation (ATAGI) has determined that to create the very best immune response, ensure the most effective clinical protection and maximise broader community coverage, the vaccine should be administered 12 weeks apart.

People who have had the first dose of the COVID-19 AstraZeneca vaccine without any serious adverse effects should have the second dose, including adults under 60 years.

Risks of vaccination

As with any vaccine, you may have some temporary side effects after receiving a COVID-19 vaccine. Common side effects after COVID-19 Vaccine AstraZeneca include:

  • injection site pain or tenderness
  • tiredness
  • headache
  • muscle pain
  • fever and chills

Most side effects are mild and temporary, going away within 1-2 days. As with any medicine or vaccine, there may be rare and/or unknown side effects.

Thrombosis with thrombocytopenia syndrome (TTS)

The COVID-19 Vaccine AstraZeneca appears to be associated with a rare side effect called thrombosis with thrombocytopenia syndrome (TTS).

What is TTS?

TTS involves blood clots (thrombosis) and low levels of blood platelets (thrombocytopenia), In Australia symptoms of TTS have occurred between 4 and 26 days post-vaccination. The blood clots can occur in different parts of the body, such as the brain (called cerebral venous sinus thrombosis or CVST) or in the abdomen. The mechanism that causes TTS is not fully understood, but it appears similar to heparin-induced thrombocytopenia (or HIT), a rare reaction to heparin treatment.

How common is TTS?

Overall the rate of TTS is estimated to be about 6 cases per million people vaccinated. But the rate is estimated to be higher (20-40 cases per million) in those under 60 years of age. These Australian estimates are not exact because there are very small numbers of TTS cases in Australia.

What symptoms does thrombosis with thrombocytopenia syndrome usually cause?

TTS is rare and occurs around 4-26 days after vaccination. Symptoms can include abdominal pain and/or severe headache that does not settle with pain relief. More information about TTS symptoms is in the patient information sheet on AstraZeneca COVID-19 vaccine and thrombosis with thrombocytopenia syndrome. People should seek medical attention immediately if they experience these symptoms.

Are any groups more at risk of TTS?

The rate of TTS reported in Australia and overseas is higher in younger adults and it may be more common in women. However cases have also been reported in men and in older people.

It is not yet clear if women are at higher risk. More women than men have been vaccinated in some countries as they are a large proportion of frontline healthcare workers and have been prioritised for vaccination.
Based on current information, we do not know if there are any pre-existing medical conditions that may contribute to developing TTS or make it worse if it occurs.

Advice for people who have had blood clots in the past

Comirnaty (Pfizer) vaccine is preferred in people who have a past history of cerebral venous sinus thrombosis or heparin-induced thrombocytopenia, given the similarities between these conditions at TTS. You can still have the AstraZeneca vaccine if you have:

  • had other types of blood clots in the past, such as deep vein thrombosis (DVT) or pulmonary embolism (PE)
  • other risk factors for blood clots.

There is no evidence that people who have had a past history of other types of blood clots have an increased risk of TTS. The overall rate of blood clots has not risen in countries which have extensively used the AstraZeneca vaccine.

Blood clots occur commonly in the population, and not all blood clots that occur after AstraZeneca COVID-19 will be caused by the vaccine. If you develop a blood clot after vaccination, your doctor can do blood tests to determine the cause.

Advice for people who have had their first dose of AstraZeneca vaccine

Almost all of the cases of TTS reported to date have occurred after the first dose of the vaccine. People who have had their first dose without any serious side effects can be confident in getting their second dose.

Advice for people with weakened immune systems (immunocompromise)

People with immunocompromise includes those who have a medical condition or are taking medications that weaken their immune system. People with immunocompromise, including those living with HIV, have a higher risk of severe illness from COVID-19, including a higher risk of severe illness and death.

The Australian Government strongly recommends people with immunocompromise receive a COVID-19 vaccine. COVID-19 Vaccine AstraZeneca does not behave like a ‘live vaccine’. The adenovirus carrier has been modified so that it cannot replicate or spread to other cells, and it cannot cause infection. It is safe in people with immunocompromise.

Clinical trials for COVID-19 Vaccine AstraZeneca did not include people with immunocompromise, but many people with such conditions have now been vaccinated worldwide. A clinical trial is being conducted of COVID-19 Vaccine AstraZeneca given to people with stable HIV infection, with results expected in a few months.

We do not know if COVID-19 Vaccine AstraZeneca is as effective in people with immunocompromise compared with the rest of the population. It is possible that it might be less effective, and so it is important to continue other preventative measures such as physical distancing after vaccination.

For more information on use of the vaccine in immunocompromised see: COVID-19 vaccination decision guide for people with immunocompromise.

Advice if you are pregnant or breastfeeding

If you are pregnant, breastfeeding, or planning pregnancy it is preferable for you to have the Pfizer COVID-19 vaccine. This is the preferred vaccine in young adults. However, you can still have the COVID-19 Vaccine AstraZeneca if the benefits of vaccination outweigh the risks for you.

Read more about COVID-19 vaccines if you are pregnant or breastfeeding.

Advice for people with a history of COVID-19

If you have ever had COVID-19 in the past, tell your immunisation provider. Your provider may advise to wait for up to 6 months after recovery before having a COVID-19 vaccine. If you have ongoing illness from COVID-19, discuss the best timing of vaccination with your treating doctor. Either COVID-19 vaccine brand can be used in people with a past history of COVID-19

COVID-19 vaccine AstraZeneca and children

COVID-19 Vaccine AstraZeneca has only been provisionally approved for use in people aged 18 years or older, and cannot be given to younger people. The risk of COVID-19, especially severe disease, in children is lower than in older adolescents and adults.

About the Pfizer Vaccine (Comirnaty)

Comirnaty (Pfizer Australia Pty Ltd) is a vaccine that can prevent people from becoming ill from COVID-19. Comirnaty does not contain any live virus, and it cannot give you COVID-19. It contains the genetic code for an important part of the SARS-CoV-2 virus called the spike protein. After getting the vaccine, your body makes copies of the spike protein. Your immune system will then learn to recognise and fight against the SARS-CoV-2 virus, which causes COVID-19. The genetic code is then broken down quickly by the body.

Two doses of Pfizer vaccine are administered between 3 and 6 weeks apart.

Benefits of the Pfizer vaccine

A very large clinical trial showed that Comirnaty is effective in preventing COVID-19 in people aged 16 years and older. People who had two doses of Comirnaty were about 95 per cent less likely to get symptomatic COVID-19 than people who did not get the vaccine. It was equally effective in people over the age of 65 years, as well as people with some stable pre-existing medical conditions.

Protection against COVID-19 starts from about 2–3 weeks after the first dose. While one dose may give some protection, it may only last for the short-term. Two doses will give optimal protection. No vaccine is 100 per cent effective, so it is possible that you can 
still get sick from COVID-19 after vaccination. We do not know how long 
the protection from Comirnaty will last. We will learn more about this 
over time. 

We currently do not know how effective COVID-19 vaccines are at preventing spread of the virus. This means that SARS-CoV-2 could potentially still infect a vaccinated person. Even if they have no symptoms or only mild symptoms they could still pass it on to others.

This is why it is important to continue other preventative measures like:

  • physical distancing
  • hand washing
  • wearing a face mask
  • COVID-19 testing and quarantine/isolation as required by your state/territory. 

If you have been vaccinated with two doses of Comirnaty, you should still get a COVID-19 test if you have symptoms that meet testing criteria according to your local health authority (e.g. fever, cough, sore throat).

Who can receive this vaccine

People aged 12 years and older can receive this COVID-19 vaccination. 

Certain groups of people are prioritised to receive vaccines first because they are at higher risk of:

  • exposure to the COVID-19 virus, for example workers in border or quarantine facilities, a healthcare facility or aged-care facility, or \
  • severe illness and death from COVID-19, for example are older or have underlying medical conditions.

Who should not receive this vaccine

You should not receive this vaccine if you have had:

  • anaphylaxis (a type of severe allergic reaction) to a previous dose of the same 
COVID-19 vaccine, or 
  • anaphylaxis after exposure to any component of a COVID-19 vaccine. 

Precautions for vaccination

People with certain conditions may need additional precautions such as staying for 30 minutes of observation after having their vaccine or consulting an allergy specialist. Tell your immunisation provider if you have had:

  • an allergic reaction to a previous dose of a COVID-19 vaccine or to an ingredient of the vaccine
  • anaphylaxis to other vaccines or to other medicines. Your provider can check to ensure there are no common ingredients with the COVID-19 vaccine you are receiving
  • mast cell disorder.

If you have a bleeding disorder or you are taking a blood-thinning medication (anticoagulant), tell your immunisation provider. Your immunisation provider can help determine whether it is safe for you to have an intramuscular injection, and help decide the best timing for injection. 

Special circumstances to discuss before vaccination 

People with precautionary conditions for Comirnaty

People with a history of any of the following conditions can receive Comirnaty but advice should be sought from a cardiologist about the best timing of vaccination and whether any additional precautions are recommended:

  • Inflammatory cardiac illness e.g., myocarditis, pericarditis, endocarditis
  • Acute rheumatic fever
  • Dilated cardiomyopathy (for people under 30 years of age)
  • Congenital heart disease
  • Severe heart failure
  • Heart transplant recipients
People with weakened immune systems (immunocompromise)

People with immunocompromise includes those who have a medical condition that weakens their immune system. It also includes those who may be taking medications that suppress their immune system. 

The Australian Government strongly recommends people with immunocompromise receive COVID-19 vaccination. Comirnaty is not a live vaccine. It is safe in people with immunocompromise.

People with immunocompromise, including those living with HIV, have a higher risk of severe illness from COVID-19, including a higher risk of death. 

Clinical trials for Comirnaty did not include people with immunocompromise, except for a small group of people with stable HIV. We do not know if Comirnaty is as effective in people with immunocompromise compared to the rest of the population. It is possible that Comirnaty might not be as effective in people with immunocompromise as it is in the general population. It is important to continue other preventative measures such as physical distancing after vaccination. 

Women who are pregnant or breastfeeding

Pregnant women should be routinely offered Comirnaty at any stage of pregnancy. If you are trying to become pregnant you do not need to delay vaccination or avoid becoming pregnant after vaccination.

Pregnant women with COVID-19 have an increased risk of severe illness and adverse pregnancy outcomes. Real-world evidence has shown that Comirnaty is safe for pregnant women and breastfeeding women. You can discuss the decision in relation to timing of vaccination with your health professional.

If you are breastfeeding, you can have Comirnaty. You do not need to stop breastfeeding after vaccination. 

People with a history of COVID-19

If you have had COVID-19 in the past, tell your immunisation provider. Your provider may advise to wait for up to six months after recovery before having a COVID-19 vaccine. If you have ongoing illness from COVID-19, discuss the best timing of vaccination with your treating doctor.

Comirnaty and children

Comirnaty has only been provisionally approved for use in people aged 16 years or older, and cannot be given to younger people. Clinical trials are currently testing Comirnaty in older children but we do not yet have the results of this trial. The risk of COVID-19, especially severe disease, in children is lower than in older adolescents and adults. 

Ensuring the safety of Comirnaty

Comirnaty and other COVID-19 vaccines have been developed quickly due to increased funding for vaccine research, and access to very large numbers of volunteers for research studies. A large clinical trial involving around 44,000 people confirmed Comirnaty to be safe and effective.

Vaccine safety and reporting adverse events

The Therapeutic Goods Administration (TGA) assesses all vaccines in Australia. This ensures that in order for a vaccine to be approved it is safe, effective and manufactured to a very high quality standard. A description of the process for approval of COVID-19 vaccines is available on the TGA website. (https://www.tga.gov.au/covid-19-vaccine-approval-process )

The safety of COVID-19 vaccines will be monitored continuously throughout the COVID-19 vaccination program. Suspected side effects can be reported to your vaccination provider or other healthcare professional. They will then make a formal report on your behalf to your state or territory health department or directly to the Therapeutic Goods Administration (TGA).

If you would prefer to report it yourself, please visit the TGA website (https://www.tga.gov.au/reporting-suspected-side-effects-associated-covid-19-vaccine ) for information on how to report suspected side effects associated with COVID-19 vaccines.

Medical experts have studied COVID-19 vaccines to make sure they are safe. Most side effects are mild and don’t last for long. As with any vaccine or medicine, there may be rare and/or unknown side effects.

You can also tell your healthcare provider if you have any side effects like a sore arm, headache, fever or something else. If you have a side effect that worries you, please call your doctor.

Further information is detailed in these announcements

https://www.health.gov.au/news/joint-statement-on-covid-19-astrazeneca-vaccine-advice-from-atagi

https://www.tga.gov.au/media-release/astrazeneca-chadox1-s-covid-19-vaccine

People should discuss this information when considering the benefits and risks of COVID-19 vaccination with their usual doctor.

Some people may still get COVID-19 after vaccination. So you must still follow public health precautions as required in your state or territory to stop the spread of COVID-19 including:

  • keep your distance – stay at least 1.5 metres away from other people
  • washing your hands often with soap and water, or use hand sanitiser
  • wear a mask, if your state or territory has advised you should
  • stay home if you are unwell with cold or flu-like symptoms andarrange to get a COVID-19 test.Vaccination providers record all vaccinations on the Australian Immunisation Register, as required by Australian law. You can view your vaccination record online through your:
    • Medicare account
    • MyGov account
    • MyHealthRecord account.

Other Resources

We have compiled a list of resources so that you may explore aspects of the vaccine relevant to you.

AstraZeneca vaccine and the COVID-19 vaccination program – Patient information
https://www.health.gov.au/resources/publications/astrazeneca-vaccine-and-the-covid-19-vaccination-program-patient-information

Healthdirect COVID-19 Vaccination Information
https://www.healthdirect.gov.au/covid-19-vaccination

Department of Health COVID-19 Vaccine Website
https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines

COVID-19 vaccination – Easy Read resources
https://www.health.gov.au/resources/collections/covid-19-vaccination-easy-read-resources

COVID-19 Vaccines – How vaccines work
This video describes how vaccines work in the body after you receive a vaccination
https://www.health.gov.au/resources/videos/covid-19-vaccines-how-vaccines-work

COVID-19 Vaccines
News and information for Australians about the development, approval process and plans for COVID-19 vaccines.
https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines

Consumer Medical Information – AstraZeneca COVID-19 Vaccine
https://www.tga.gov.au/sites/default/files/cmi-approved-covid19-vaccine-az.pdf

TGA Information about the AstraZeneca Vaccine
https://www.tga.gov.au/covid-19-vaccine-astrazeneca-chadox1-s

COVID-19 vaccines – Patient Resources
https://www.health.gov.au/resources/collections/covid-19-vaccination-patient-resources

STEP 4 – Book Your Appointment

If you have completed all of the above steps then you are ready to book your appointment.

YOUF FIRST AND SECOND DOSE MUST BE THE SAME BRAND OF VACCINE

PLEASE DO NOT PHONE IF POSSIBLE – UTILISE OUR ONLINE BOOKING SERVICE BY CLICKING ON THE RELEVANT BUTTON BELOW

DO NOT ATTEND YOUR APPOINTMENT IF YOU:
  • HAVE BEEN IN CONTACT WITH A SUSPECTED CASE OF COVID-19 OR
  • ARE AWAITING FOR A COVID-19 SWAB RESULT OR
  • HAVE ANY OF THE FOLLOWING SYMPTOMS
    • SORE THROAT
    • FEVER
    • COUGH
    • RUNNY NOSE
    • SHORTNESS OF BREATH



SECOND DOSE

ASTRAZENECA

For patients who had AstraZeneca vaccine as their first dose

SECOND DOSE

PFIZER

For patients who had the Pfizer vaccine as their first dose


If you are a new patient of the practice, you MUST bring your Medicare or DVA card along with a form of photo identification. If you have pre-existing illnesses or allergies, a health summary from your usual medical practitioner is also recommended.

Please arrive at least 10 minutes before your appointment to allow time for registration to be completed. Our registration form may be downloaded HERE so that you may fill it in before your attendance.


STEP 5 – After Your Vaccination

After waiting for 15 minutes, you are free to leave the premises provided there are no immediate side effects.

You will need to schedule an appointment for your SECOND COVID-19 vaccine dose:

  • 3-6 weeks later for the Pfizer vaccine or
  • 4-12 weeks later for the AstraZeneca vaccine
Vaccine Side effects

You may experience minor side effects following your vaccination against COVID-19. Most side effects last no more than a couple of days and you should recover without any problems.

Common reactions to any vaccine include:

  • pain, redness or swelling at the injection site
  • mild fever
  • nausea

Serious reactions, such as allergic reactions, are extremely rare. If you have any concerns about a vaccine, ask your usual doctor.

Any injectable vaccine can also cause an allergic reaction in some people.

Contact your healthcare provider immediately or go straight to the emergency department at your nearest hospital if you notice any of these symptoms of an allergic reaction:

  • rash, itching or hives on the skin
  • swelling of the face, lips, tongue or other parts of the body
  • shortness of breath, wheezing or difficulty breathing
  • fainting, dizziness, feeling lightheaded (due to a drop in blood pressure)

After you have received medical advice for any side effects that you experience, you can report them to the Therapeutic Goods Administration (TGA) at https://www.tga.gov.au/reporting-problems. By reporting side effects, you’re helping provide more information on the safety of vaccines.

Be sure to tell your doctor that you have recently received the vaccine. For symptoms which are not urgent, you can see your regular healthcare provider (usually your GP).

You can also tell your healthcare provider if you have any side effects like a sore arm, headache, fever or something else. If you have a side effect that worries you, please call your doctor.

Use the COVID-19 vaccine side effects symptom checker (https://www.healthdirect.gov.au/covid-19-vaccine-side-effect-checker) if you have concerns about any symptoms after your vaccine. The checker is also available through the National Coronavirus Helpline, 1800 020 080, 24 hours a day.

More information may be found at this link:
https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/learn-about-covid-19-vaccines/what-happens-after-i-am-vaccinated-for-covid-19

If you believe that you may have a side effect, you may report this directly to the TGA. More information regarding reporting is found at these links

Victorian Surveillance of Adverse Effects following Vaccination in the Community ( SAEFVIC)
https://www.safevac.org.au/Home/Info/VIC

Report directly to the TGA (Therapeutic Goods Administration)
https://www.tga.gov.au/reporting-problems

Report to the NPS MedicineWise Adverse Medicine Events line
Consumers can make a report and obtain advice from a pharmacist by calling the NPS MedicineWise Adverse Medicine Events line on 1300 134 237 (8am-8pm seven days a week)

AstraZeneca vaccine side effects

The TGA has provisionally approved COVID-19 Vaccine AstraZeneca for people aged over 18 years.  However, the Australian Technical Advisory Group on Immunisation (or ATAGI) recommends that the Pfizer vaccine be given to adults under 60 years who have not already received a first dose of the AstraZeneca vaccine.

ATAGI issued these recommendations after noting evidence of a very rare but serious side effect that involves blood clots with low blood platelet counts after AstraZeneca vaccination. The syndrome is called ‘thrombosis with thrombocytopenia’.

Less-serious side effects of this vaccine include:

  • tenderness, pain, warmth, redness, itching or swelling at the injection site
  • feeling unwell
  • tiredness
  • chills, fever or feeling feverish
  • headache
  • nausea
  • muscle aches or pain
  • joint pain

If you experience a less-serious side effect but you’re worried, speak to your doctor or healthcare provider. You can take medicines containing paracetamol if you need relief from pain or fever.

Serious side effects of COVID-19 Vaccine AstraZeneca

The Australian Technical Advisory Group on Immunisation (ATAGI) has noted evidence of a very rare but serious side effect involving blood clotting (thrombosis) with low blood platelet count (thrombocytopenia) following AstraZeneca vaccination.

People should seek medical attention immediately if they experience these symptoms:

  • a severe persistent headache with additional features:
    • appears at least 4 days after vaccination
    • does not improve with simple painkillers
    • may be worse when lying down or accompanied by nausea and vomiting
  • neurological symptoms such as:
    • blurred vision 
    • difficulty with speech
    • drowsiness 
    • seizures 
  • shortness of breath or chest pain
  • a swollen leg
  • persistent abdominal (belly) pain
  • tiny blood spots under the skin away from the site of injection together with symptoms above.

Pfizer vaccine side effects

Australia’s Therapeutic Goods Administration (TGA) has provisionally approved the Pfizer vaccine, COMIRNATY, for people aged over 16 years.

Very common side effects of this vaccine include:

  • pain or swelling at the injection site
  • tiredness
  • headache
  • muscle pain
  • chills or fever
  • joint pain
  • nausea

Common side effects of COMIRNATY include:

  • redness at the injection site

Uncommon side effects of COMIRNATY include:

  • enlarged lymph nodes
  • feeling unwell
  • pain in your arm or leg
  • insomnia
  • itching at the injection site

If you experience a very common, common or uncommon side effect and you’re worried, speak to your doctor.

A rare side effect of COMIRNATY is temporary facial drooping on one side. If you or someone else experiences this side effect, call your doctor straight away or go straight to a hospital emergency department.

A side effect of unknown frequency of COMIRNATY is severe allergic reaction. If you or someone else experiences this, call your doctor straight away or go straight to a hospital emergency department.

A very rare side effect is myocarditis and/or pericarditis after vaccination with Pfizer COMIRNATY

The symptoms include:

  • chest pain, pressure or discomfort
  • palpitations (irregular heartbeat, skipped beats or ‘fluttering’).
  • syncope (fainting)
  • shortness of breath
  • pain with breathing.

Symptoms typically start within a few days after vaccination (median 2 days). People who experience any of these symptoms after receiving Comirnaty should seek prompt medical attention. People who feel well and do not have any of these symptoms after vaccination can continue with their usual physical activity and do not routinely need to avoid physical exertion. People who already have underlying heart dysfunction should seek medical attention for new onset or worsening of pre-existing symptoms following vaccination.

AusVaxSafety’s ACTIVE follow-up after your COVID-19 vaccination

What is AusVaxSafety?

AusVaxSafety is a national system for monitoring vaccine safety in Australia. The system is led by the National Centre for Immunisation Research and Surveillance (NCIRS). It is funded by the Australian Government Department of Health.

AusVaxSafety monitoring vaccine safety of COVID-19 vaccines

In partnership with the Australian state and territory health departments, AusVaxSafety is following up people who receive a COVID-19 vaccine by sending them an SMS or email with a short survey that asks if they experienced any adverse event following vaccination.

How does it work?

These surveys give you the opportunity to report any adverse events you have after receiving the COVID-19 vaccine. Depending on your survey responses, your state/territory health department or immunisation provider may call you to collect more details.

What happens to the information you provide?

Survey responses will contribute to the national COVID-19 vaccine safety surveillance that AusVaxSafety is conducting.

What about your personal data?

AusVaxSafety only receives responses that are ‘de-identified’ to protect your privacy. This means any information that could identify you or your child will be removed.

COVID-19 testing after vaccination

Some side effects from COVID-19 vaccination might be similar to symptoms of COVID-19 
(e.g. fever). However, COVID-19 Vaccine AstraZeneca does not contain any live SARS-CoV-2 virus and cannot cause COVID-19. You may notneed to get a COVID-19 test or isolate:

  • if you develop general symptoms like fever, headache or tiredness in the first two days after vaccination, and 
  • if you are sure that you don’t have any respiratory symptoms (e.g. runny nose, cough, sore throat, loss of smell or loss of taste). 

However, you should check the current guidelines in your state/territory for the most up-to-date information. This advice may change in the event of a COVID-19 outbreak in your local area. You may still need to get a COVID-19 test if you meet other criteria, for example if you are a close contact of a known COVID-19 case. If in doubt, seek medical assessment.

STEP 6 – Proof of Vaccination

You can get an immunisation history statement or COVID-19 digital certificate to show proof of your vaccinations.

How you get proof depends on your situation. This includes if you need to create a myGov account or link services, or enrol in Medicare.

If you’re 14 or older, you’ll need to get your own immunisation history statement or digital certificate using either your:

If you’re not eligible for Medicare, you can still get your immunisation history statement online through myGov.

You can also call the Australian Immunisation Register (1800 653 809 Monday to Friday 8 am to 5 pm) and ask them to send your immunisation history statement or COVID-19 digital certificate to you. It can take up to 14 days for your statement or certificate to arrive in the post.

More information at these links:

Coronavirus Victoria site explaining how to get your COVID-19 digital certificate
https://www.coronavirus.vic.gov.au/get-your-covid-19-digital-certificate

Services Australia web page explains how to obtain proof of vaccination
https://www.servicesaustralia.gov.au/individuals/subjects/getting-help-during-coronavirus-covid-19/covid-19-vaccinations/how-get-proof-your-covid-19-vaccinations

error: Content is protected !!